The Conversation (0)
NeoTract, a wholly owned subsidiary of Teleflex (NYSE:TFX) focused on addressing unmet needs in the field of urology, announced the presentation of new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association (AUA) in Toronto, Ontario, from a study of the company’s novel UroLift System for patients with Benign …
NeoTract, a wholly owned subsidiary of Teleflex (NYSE:TFX) focused on addressing unmet needs in the field of urology, announced the presentation of new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association (AUA) in Toronto, Ontario, from a study of the company’s novel UroLift System for patients with Benign Prostatic Hyperplasia (BPH).
As quoted in the press release:
Data presented at the 2018 Annual Meeting of the New England Section of the AUA by Campbell F. Bryson, M.D., chief urology resident of Yale New Haven Hospital in Princeton, N.J., from a single-center, first-time study closely resembles results from the pivotal L.I.F.T trial, showing robust improvements in symptoms and quality of life for patients with BPH who received the UroLift System treatment in a real-world setting.
“The results of these numerous real-world studies help to further validate the many advantages of the UroLift System for patients with BPH in the real world,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are proud to be improving the lives of patients suffering with the symptoms of BPH by providing a safe and effective treatment that provides rapid relief and allows men to stop or reduce BPH medications, without compromising sexual function.”